Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?

Strong efficacy data and a desperate need for new gout therapies outweigh the potential cardiovascular risk associated with Takeda's febuxostat, an FDA advisory committee determined in recommending approval of the drug during a Nov. 24 meeting

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet